Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
Primary Industries
- Drugs
- Tobacco
- Pharmaceuticals
- Delivery
- Therapeutic
- Chemicals
- Nicotine
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 1479
IPSCIO Record ID: 2048
IPSCIO Record ID: 570
The technology refers to certain intellectual property encompassing a new type of non-invasive drug delivery system more commonly known as a transdermal patch.
Passive drug delivery patches have applications including smoking cessation (nicotine), birth control and hormone replacement therapy (estradiol), and angina (nitroglycerine). By contrast, active transdermal drug delivery systems allow certain drugs to be delivered through the skin many times faster than passive transdermal patches.
IPSCIO Record ID: 26307
China – Patent CN1271960C
Canada – Patent Application CA2414377
Mexico – Patent Application MXPA03000125
Japan – Patent Application JP2004500901T
Brazil – Patent Application BR0017258
PCT – Patent Application WO0200046
This invention relates generally to methods, devices and agents for the removal of nucleophilic toxins present in tobacco and tobacco smoke, without affecting nicotine delivery. Nucleophilic toxins are removed by the passage of tobacco smoke or air containing tobacco smoke through a nucleophilic toxin-removing filter device. Agents may also be incorporated into smoking and smokeless tobacco to prevent volatilization and absorption, respectively, of nucleophilic toxins. Dosimetry of nucleophilic tobacco combustion products is used to monitor toxin exposure.
The technology fundamental to Licensee is protected under U.S. Patent number 6,119,701, entitled 'Methods, agents and devices for removing nucleophilic toxins from tobacco and tobacco smoke'. This invention provides methods, devices and agents for the removal of nucleophilic toxins present in tobacco and tobacco smoke, without the removal of nicotine. The filter element of a tobacco smoking device or an air filtration device used in conjunction with a tobacco smoking device may comprise chemical moieties reactive with nucleophilic compounds, or agents that trap nucleophilic compounds may be incorporated into the filter element of tobacco smoking device such as a cigarette, cigar, pipe, or in a separate filter through which tobacco smoke passes before entering the mouth. The agents may also be incorporated into air filters for removing tobacco combustion product toxins from room air. The agents may also be incorporated into smoking or smokeless tobacco to remove toxins.
IPSCIO Record ID: 28258
IPSCIO Record ID: 315809
– an exclusive license, with the right to sublicense, to research, develop, import, use, market, sell, have sold, offer for sale and otherwise commercialize the Product in the Field in the U.S., and
– a co-exclusive license, with the right to sublicense, to manufacture and have manufactured the Product for the purposes of researching, developing, importing, using, marketing, selling, having sold, offering for sale and otherwise commercializing the Product in the Field in the U.S.; and,
– a non-exclusive license, with the right to sublicense, solely and to the extent needed to conduct clinical and non-clinical development activities with respect to the Product in the Field outside the U.S.
Product shall mean the drug-device combination product that is comprised of Loxapinc delivered by the Staccato Device, which has been or is during the Term approved by the FDA in the U.S., which form of product is currently designated as Adasuve®.
Staccato Device shall mean any hand-held, fixed-dosage device for the administration of API(s), which relies on Licensors proprietary heat package and stainless steel substrate to rapidly heat and create a condensation vaporized aerosol of APl(s) that allows the delivery of API(s) through deep lung inhalation, where the device is known as or based on, but may or may not be referred to, as the Staccato® system.
The patents relate to the Delivery of antipsychotics through an inhalation route.
IPSCIO Record ID: 147203
(i) use of cotinine for body weight management, including but not limited to US. Patent Application/Serial No. 07/964,277, filed October 21, 1992, and issued as U.S. Patent No. 5,643,928, and corresponding foreign patent applications or patents listed;
(ii) therapeutic method to alleviate the craving associated with cessation of tobacco with cotinine, including but not limited to U.S. Patent Application/Serial No. 07/885,314, filed May 18, 1992, and issued as U.S. Patent No. 5,596,007, and corresponding foreign patent applications or patents listed
(iii) use of cotinine to assist in the cessation of tobacco smoking, including but not limited to U.S. Patent Application/Serial No. 07/971,573, filed November 5, 1992, and corresponding foreign patent applications listed;
(iv) use of cotinine to assist in the cessation of tobacco smoking, including but not limited to U.S. Patent Application/Serial No. 08/293,585, filed August 22, 1994, and issued as U.S. Patent No. 5,612,357, and corresponding foreign patent applications or patents listed; and
(v) use of cotinine to alleviate tobacco withdrawal syndrome, including but not limited to U.S. Patent Application/Serial No. 08/691,888, filed August 1, 1996, and issued as U.S. Patent No. 5,747,512, and corresponding foreign patent applications or patents listed.
Phase I Studies shall mean pilot efficacy studies.
IPSCIO Record ID: 300758
The patents include
Nucleic Acid Sequences and Their Use in Modifying Alkaloid Production in Plants,
Methods of Modifying Alkaloid Production in Plants,
Nucleic Acid Encoding N-methylputrescine Oxidase and Uses Thereof, and,
Nucleic Acid Sequences Encoding Transcription Factors Regulating Alkaloid Biosynthesis and Their Use in Modifying Plant Metabolism.
Licensor is a plant biotechnology company and a global leader in modifying the content of nicotinic alkaloids in tobacco plants through genetic engineering and plant breeding.
The Field means all uses of Nicotiana plants and products produced therefrom.
